Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Raised by Victory Capital Management Inc.

Victory Capital Management Inc. raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 198.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,833 shares of the medical equipment provider’s stock after buying an additional 51,128 shares during the period. Victory Capital Management Inc. owned about 0.11% of Lantheus worth $8,432,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LNTH. Moloney Securities Asset Management LLC acquired a new stake in Lantheus during the 3rd quarter valued at $1,066,000. Hancock Whitney Corp grew its position in Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Lantheus in the 2nd quarter valued at approximately $290,000. Van ECK Associates Corp lifted its position in Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after buying an additional 21,604 shares in the last quarter. Finally, Swedbank AB boosted its stake in shares of Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after buying an additional 125,843 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Up 1.0 %

Shares of Lantheus stock opened at $87.32 on Friday. The stock has a market capitalization of $6.07 billion, a P/E ratio of 14.53 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a 50-day simple moving average of $103.76 and a 200 day simple moving average of $96.59.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.